{
  "first_published_at": "2011-10-13", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON131932", 
  "title": "Calcium and vitamin D: studies of cardiovascular risk do not support prescribing changes", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\", \"nutrition-dietetics\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\", \"Nutrition and dietetics\"]}", 
  "_document_number": 136, 
  "label": null, 
  "icon": null, 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism", 
    "nutrition-dietetics"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Calcium and vitamin D: studies of cardiovascular risk do not support prescribing changes</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>A recent meta-analysis has raised concerns about a possible modest increase in the risk of some cardiovascular events in postmenopausal women who use calcium and vitamin D supplements to prevent osteoporotic fractures. However, there are limitations to the data and no change to prescribing practice is currently recommended.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>A research article<cite>Bolland MJ, et al. BMJ 2010; 341: c3691</cite> in 2010 by Bolland and colleagues seemed to show that calcium supplements without coadministered vitamin D are associated with a modest increased risk of myocardial infarction (MI, hazard ratio [HR] 1.31 [95% CI 1.02&ndash;1.67]; p=0.035). Non-significant increases occurred in the incidence of stroke and death; the risk for the composite endpoint (MI, stroke, or sudden death) was of borderline significance (HR 1.18 [1.00&ndash;1.39], p=0.057).</p><p>The researchers have recently published<cite>Bolland MJ, et al. BMJ 2011; 342: d2040</cite> a reanalysis of data from a large randomised controlled trial (the Women&rsquo;s Health Initiative study&mdash;WHI), and a further meta-analysis of trials of calcium with or without vitamin D versus placebo.&nbsp;&nbsp;</p><p>In the reanalysis of the WHI trial of calcium plus vitamin D versus placebo, the risk of clinical MI was slightly increased in women not self-medicating with calcium supplements at baseline who were randomly assigned to calcium plus vitamin D (HR 1.22 [1.00&ndash;1.50]; p=0.054), but this was of borderline significance. There were 209 events of clinical MI in the calcium plus vitamin D group compared with 168 events in the placebo group (an incidence of 3.5 compared with 2.9 per 1000 patient-years). Overall, the reanalyses do not provide conclusive evidence of clinically significant harm, partly because all-cause mortality was not increased in this group (HR 0.99 [0.86&ndash;1.14]; p=0.89). Furthermore, for women in WHI who self-medicated with calcium supplements at baseline and who were randomly assigned to calcium plus vitamin D, all-cause mortality was significantly decreased compared with placebo (HR 0.84 [0.73&ndash;0.97]; p=0.01).&nbsp;</p><p>Inclusion of the WHI subgroup findings (women not self-medicating with calcium supplements at baseline only) in a new meta-analysis of trials of calcium plus vitamin D versus placebo resulted in a slightly lower and more precise risk estimate for MI and stroke associated with calcium plus vitamin D (relative risk 1.16 [95% CI 1.02&ndash;1.32], p=0.02). However, there was no increase in the risk of all-cause death.</p><p>The reanalysis was reviewed by the Commission on Human Medicines (CHM) and its expert advisors. There were concerns over methodology and data interpretation, and they advised that the data did not provide convincing evidence that calcium and vitamin D supplements were associated with an increased risk of cardiovascular events. They considered that any further research should be carefully evaluated and that it would be desirable to study separately the effects of calcium and vitamin D on cardiovascular risk.</p><p>Concerns over methodology and data interpretation included that, for the reanalysis, the increased risk of MI (or the composite of MI or stroke) in women not taking calcium supplements at baseline was only just significant and there was no increased risk in overall mortality in that group. Furthermore, for the new meta-analysis, concerns included: inclusion of trials with different endpoints; exclusion of more than half the participants in the WHI trial; a small, marginally significant increased risk of MI and stroke in the subgroup but not in the overall WHI trial; and multiple testing, which increases the risk of false-positive results. Finally, there may be alternative explanations for the findings, such as misclassification bias whereby upper gastrointestinal side effects (which are common with calcium supplements) are misclassified as symptoms of cardiac disease.</p><p><br></p><div class=\"dull_highlight\">\r\n\t\t\t<font class=\"h4\">Advice for healthcare professionals:</font>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Prescribers should consider the potential benefits and risks of using calcium and vitamin D for prevention of osteoporotic fractures on an individual basis in line with NICE guidance on drugs for the <a href=\"http://www.nice.org.uk/TA160\" target=\"_blank\">primary</a> and <a href=\"http://www.nice.org.uk/TA161\" target=\"_blank\">secondary prevention of osteoporosis</a>. Prescribers should consider offering these supplements to postmenopausal women who receive treatment for osteoporosis (eg, with bisphosphonates), unless they are confident that the patient has an adequate calcium intake and is vitamin D replete</li>\r\n\t\t\t\t<li><a href=\"http://www.nos.org.uk/page.aspx?pid=248&srcid=264\" target=\"_blank\">The National Osteoporosis Society</a> advises that increasing dietary intake in those with low intakes of calcium and vitamin D is considered preferable to supplements. They also advise that supplementation may be warranted, but needs to be done with consideration based on dietary intake</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p><font class=\"h4\">Further information:</font></p><p>BNF section 6.6 <a href=\"http://bnf.org/bnf/bnf/current/100042.htm\" target=\"_blank\">Drugs affecting bone metabolism&mdash;osteoporosis</a></p><p><br><em>Article citation: Drug Safety Update Oct 2011, vol 5 issue 3: H1.</em><br></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>A research article<cite>Bolland MJ, et al. BMJ 2010; 341: c3691</cite> in 2010 by Bolland and colleagues seemed to show that calcium supplements without coadministered vitamin D are associated with a modest increased risk of myocardial infarction (MI, hazard ratio [HR] 1.31 [95% CI 1.02&#8211;1.67]; p=0.035). Non-significant increases occurred in the incidence of stroke and death; the risk for the composite endpoint (MI, stroke, or sudden death) was of borderline significance (HR 1.18 [1.00&#8211;1.39], p=0.057).</p><p>The researchers have recently published<cite>Bolland MJ, et al. BMJ 2011; 342: d2040</cite> a reanalysis of data from a large randomised controlled trial (the Women&#8217;s Health Initiative study&#8212;WHI), and a further meta-analysis of trials of calcium with or without vitamin D versus placebo.&#160;&#160;</p><p>In the reanalysis of the WHI trial of calcium plus vitamin D versus placebo, the risk of clinical MI was slightly increased in women not self-medicating with calcium supplements at baseline who were randomly assigned to calcium plus vitamin D (HR 1.22 [1.00&#8211;1.50]; p=0.054), but this was of borderline significance. There were 209 events of clinical MI in the calcium plus vitamin D group compared with 168 events in the placebo group (an incidence of 3.5 compared with 2.9 per 1000 patient-years). Overall, the reanalyses do not provide conclusive evidence of clinically significant harm, partly because all-cause mortality was not increased in this group (HR 0.99 [0.86&#8211;1.14]; p=0.89). Furthermore, for women in WHI who self-medicated with calcium supplements at baseline and who were randomly assigned to calcium plus vitamin D, all-cause mortality was significantly decreased compared with placebo (HR 0.84 [0.73&#8211;0.97]; p=0.01).&#160;</p><p>Inclusion of the WHI subgroup findings (women not self-medicating with calcium supplements at baseline only) in a new meta-analysis of trials of calcium plus vitamin D versus placebo resulted in a slightly lower and more precise risk estimate for MI and stroke associated with calcium plus vitamin D (relative risk 1.16 [95% CI 1.02&#8211;1.32], p=0.02). However, there was no increase in the risk of all-cause death.</p><p>The reanalysis was reviewed by the Commission on Human Medicines (CHM) and its expert advisors. There were concerns over methodology and data interpretation, and they advised that the data did not provide convincing evidence that calcium and vitamin D supplements were associated with an increased risk of cardiovascular events. They considered that any further research should be carefully evaluated and that it would be desirable to study separately the effects of calcium and vitamin D on cardiovascular risk.</p><p>Concerns over methodology and data interpretation included that, for the reanalysis, the increased risk of MI (or the composite of MI or stroke) in women not taking calcium supplements at baseline was only just significant and there was no increased risk in overall mortality in that group. Furthermore, for the new meta-analysis, concerns included: inclusion of trials with different endpoints; exclusion of more than half the participants in the WHI trial; a small, marginally significant increased risk of MI and stroke in the subgroup but not in the overall WHI trial; and multiple testing, which increases the risk of false-positive results. Finally, there may be alternative explanations for the findings, such as misclassification bias whereby upper gastrointestinal side effects (which are common with calcium supplements) are misclassified as symptoms of cardiac disease.</p><p><br></p><div class=\"dull_highlight\">\r\n\t\t\t<font class=\"h4\">Advice for healthcare professionals:</font>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Prescribers should consider the potential benefits and risks of using calcium and vitamin D for prevention of osteoporotic fractures on an individual basis in line with NICE guidance on drugs for the <a href=\"http://www.nice.org.uk/TA160\" target=\"_blank\">primary</a> and <a href=\"http://www.nice.org.uk/TA161\" target=\"_blank\">secondary prevention of osteoporosis</a>. Prescribers should consider offering these supplements to postmenopausal women who receive treatment for osteoporosis (eg, with bisphosphonates), unless they are confident that the patient has an adequate calcium intake and is vitamin D replete</li>\r\n\t\t\t\t<li><a href=\"http://www.nos.org.uk/page.aspx?pid=248&amp;srcid=264\" target=\"_blank\">The National Osteoporosis Society</a> advises that increasing dietary intake in those with low intakes of calcium and vitamin D is considered preferable to supplements. They also advise that supplementation may be warranted, but needs to be done with consideration based on dietary intake</li>\r\n\t\t\t</ul></div><p>&#160;</p><p><font class=\"h4\">Further information:</font></p><p>BNF section 6.6 <a href=\"http://bnf.org/bnf/bnf/current/100042.htm\" target=\"_blank\">Drugs affecting bone metabolism&#8212;osteoporosis</a></p><p><br><em>Article citation: Drug Safety Update Oct 2011, vol 5 issue 3: H1.</em><br></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-10-01", 
  "date_last_modified": "2011-10-13", 
  "_assets": [], 
  "_item_id": 136, 
  "summary": "A recent meta-analysis has raised concerns about a possible modest increase in the risk of some cardiovascular events in postmenopausal women who use calcium and vitamin D supplements to prevent osteoporotic fractures. However, there are limitations to the data and no change to prescribing practice is currently recommended.", 
  "body": "Article date: October 2011\n\nA research article[^1] in 2010 by Bolland and colleagues seemed to show that calcium supplements without coadministered vitamin D are associated with a modest increased risk of myocardial infarction (MI, hazard ratio [HR] 1.31 [95% CI 1.02–1.67]; p=0.035). Non-significant increases occurred in the incidence of stroke and death; the risk for the composite endpoint (MI, stroke, or sudden death) was of borderline significance (HR 1.18 [1.00–1.39], p=0.057). \n\nThe researchers have recently published[^2] a reanalysis of data from a large randomised controlled trial (the Women’s Health Initiative study—WHI), and a further meta-analysis of trials of calcium with or without vitamin D versus placebo.  \n\nIn the reanalysis of the WHI trial of calcium plus vitamin D versus placebo, the risk of clinical MI was slightly increased in women not self-medicating with calcium supplements at baseline who were randomly assigned to calcium plus vitamin D (HR 1.22 [1.00–1.50]; p=0.054), but this was of borderline significance. There were 209 events of clinical MI in the calcium plus vitamin D group compared with 168 events in the placebo group (an incidence of 3.5 compared with 2.9 per 1000 patient-years). Overall, the reanalyses do not provide conclusive evidence of clinically significant harm, partly because all-cause mortality was not increased in this group (HR 0.99 [0.86–1.14]; p=0.89). Furthermore, for women in WHI who self-medicated with calcium supplements at baseline and who were randomly assigned to calcium plus vitamin D, all-cause mortality was significantly decreased compared with placebo (HR 0.84 [0.73–0.97]; p=0.01). \n\nInclusion of the WHI subgroup findings (women not self-medicating with calcium supplements at baseline only) in a new meta-analysis of trials of calcium plus vitamin D versus placebo resulted in a slightly lower and more precise risk estimate for MI and stroke associated with calcium plus vitamin D (relative risk 1.16 [95% CI 1.02–1.32], p=0.02). However, there was no increase in the risk of all-cause death.\n\nThe reanalysis was reviewed by the Commission on Human Medicines (CHM) and its expert advisors. There were concerns over methodology and data interpretation, and they advised that the data did not provide convincing evidence that calcium and vitamin D supplements were associated with an increased risk of cardiovascular events. They considered that any further research should be carefully evaluated and that it would be desirable to study separately the effects of calcium and vitamin D on cardiovascular risk.\n\nConcerns over methodology and data interpretation included that, for the reanalysis, the increased risk of MI (or the composite of MI or stroke) in women not taking calcium supplements at baseline was only just significant and there was no increased risk in overall mortality in that group. Furthermore, for the new meta-analysis, concerns included: inclusion of trials with different endpoints; exclusion of more than half the participants in the WHI trial; a small, marginally significant increased risk of MI and stroke in the subgroup but not in the overall WHI trial; and multiple testing, which increases the risk of false-positive results. Finally, there may be alternative explanations for the findings, such as misclassification bias whereby upper gastrointestinal side effects (which are common with calcium supplements) are misclassified as symptoms of cardiac disease.\n\n  \n\n\nAdvice for healthcare professionals:  \n  \n  * Prescribers should consider the potential benefits and risks of using calcium and vitamin D for prevention of osteoporotic fractures on an individual basis in line with NICE guidance on drugs for the [primary](http://www.nice.org.uk/TA160) and [secondary prevention of osteoporosis](http://www.nice.org.uk/TA161). Prescribers should consider offering these supplements to postmenopausal women who receive treatment for osteoporosis (eg, with bisphosphonates), unless they are confident that the patient has an adequate calcium intake and is vitamin D replete  \n  * [The National Osteoporosis Society](http://www.nos.org.uk/page.aspx?pid=248&srcid=264) advises that increasing dietary intake in those with low intakes of calcium and vitamin D is considered preferable to supplements. They also advise that supplementation may be warranted, but needs to be done with consideration based on dietary intake  \n  \n \n\nFurther information:\n\nBNF section 6.6 [Drugs affecting bone metabolism—osteoporosis](http://bnf.org/bnf/bnf/current/100042.htm)\n\n  \nArticle citation: Drug Safety Update Oct 2011, vol 5 issue 3: H1.  \n\n\n[^1]: Bolland MJ, et al. BMJ 2010; 341: c3691\n\n[^2]: Bolland MJ, et al. BMJ 2011; 342: d2040\n"
}